100 related articles for article (PubMed ID: 12638227)
1. [Bone loss induced by GnRHa treatment in women].
Matsuo H
Nihon Rinsho; 2003 Feb; 61(2):314-8. PubMed ID: 12638227
[TBL] [Abstract][Full Text] [Related]
2. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness of bisphosphonate administration during Gn-RH agonist therapy for endometriosis].
Aisaka K
Nihon Rinsho; 2009 May; 67(5):1027-30. PubMed ID: 19432128
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey ES
Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596
[TBL] [Abstract][Full Text] [Related]
5. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
Chwalisz K; Surrey E; Stanczyk FZ
Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
[TBL] [Abstract][Full Text] [Related]
6. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
7. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
8. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of bisphosphonate administration for prevention of osteopenia during Gn-RH agonist therapy of endometriosis].
Aisaka K
Nihon Rinsho; 2007 Nov; 65 Suppl 9():360-4. PubMed ID: 18161132
[No Abstract] [Full Text] [Related]
10. [A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy].
Niu ZR; Yue XJ; Kong QY; Wang YF; Yao YQ
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):338-43. PubMed ID: 24016475
[TBL] [Abstract][Full Text] [Related]
11. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
[TBL] [Abstract][Full Text] [Related]
12. Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms.
Adashi EY
Hum Reprod; 1994 Jul; 9(7):1380-97. PubMed ID: 7962453
[TBL] [Abstract][Full Text] [Related]
13. Current approaches to optimizing the treatment of endometriosis in adolescents.
Laufer MR
Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis.
Akira S; Mine K; Kuwabara Y; Takeshita T
Med Sci Monit; 2009 Jan; 15(1):CR1-4. PubMed ID: 19114964
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of add-back therapy with various natural oestrogens on bone metabolism in rats administered a long-acting gonadotrophin-releasing hormone agonist.
Wang Y; Yano T; Kikuchi A; Yano N; Matsumi H; Ando K; Kasai Y; Watanabe M; Okagaki R; Osuga Y; Taketani Y
J Endocrinol; 2000 May; 165(2):467-73. PubMed ID: 10810310
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone agonists: emerging modification of treatment regimens.
Hodgen GD
Curr Opin Obstet Gynecol; 1991 Jun; 3(3):352-7. PubMed ID: 1813003
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
Sadler Gallagher J; Feldman HA; Stokes NA; Laufer MR; Hornstein MD; Gordon CM; DiVasta AD
J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
[TBL] [Abstract][Full Text] [Related]
19. Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density?
Agarwal SK
J Reprod Med; 2002 Jul; 47(7):530-4. PubMed ID: 12170527
[TBL] [Abstract][Full Text] [Related]
20. Dose effects of progesterone in add-back therapy during GnRHa treatment.
Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
